SPAS(SH:603168)2019-10-29 16:00Financial Performance - Operating revenue for the first nine months was CNY 404,424,394.81, a decrease of 18.54% year-on-year[5] - Net profit attributable to shareholders of the listed company decreased by 49.75% to CNY 39,156,181.78 compared to the same period last year[5] - Basic earnings per share dropped by 50.00% to CNY 0.12[6] - The weighted average return on net assets decreased by 2.03 percentage points to 2.61%[6] - Net profit for the first three quarters of 2019 was CNY 51,356,807.97, a decrease from CNY 98,596,091.01 in the same period of 2018, representing a decline of approximately 48.0%[35] - Total profit for the first three quarters of 2019 was CNY 60,682,317.54, down from CNY 116,031,529.00 in the same period of 2018, representing a decline of approximately 47.7%[34] - The net profit for Q3 2019 was CNY 13.46 million, down 50.2% from CNY 27.04 million in Q3 2018[31] - The total profit for the first three quarters of 2019 reached CNY 48.48 million, a decline of 49.3% from CNY 95.36 million in the same period of 2018[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,648,557,468.28, showing a negligible change of 0.00% compared to the end of the previous year[5] - The company's total liabilities decreased from 167.41 million RMB at the end of 2018 to 128.22 million RMB as of September 30, 2019, reflecting a reduction of about 23.4%[22] - The company's current assets totaled 944.30 million RMB as of September 30, 2019, compared to 911.47 million RMB at the end of 2018, indicating an increase of approximately 3.6%[20] - The company's cash and cash equivalents increased by 30.80% to ¥189,878,832.94, compared to ¥145,164,499.82 in the previous period[9] - The company's cash and cash equivalents increased to 189.88 million RMB as of September 30, 2019, up from 145.16 million RMB at the end of 2018, representing a growth of approximately 30.8%[20] - The company's total equity increased to ¥1,586,500,666.56 from ¥1,535,143,858.59, reflecting a growth of 3.3%[27] Cash Flow - Net cash flow from operating activities for the first nine months was CNY 52,971,706.23, down 29.75% from the previous year[5] - Cash flow from operating activities for the first three quarters of 2019 was CNY 52,971,706.23, down from CNY 75,400,670.50 in the same period of 2018, reflecting a decline of approximately 29.7%[37] - The company reported a net cash outflow from investing activities of CNY -8,257,373.11 for the first three quarters of 2019, compared to CNY -325,166,602.05 in the same period of 2018[38] - The cash inflow from operating activities was $415.56 million, while cash outflow was $351.03 million, resulting in a net cash flow of $64.54 million[40] - The cash flow from financing activities for the first three quarters of 2019 was CNY -49,629,615.20, indicating a net outflow[38] Shareholder Information - The company reported a total of 24,964 shareholders at the end of the reporting period[7] - The largest shareholder, Chen Dekang, holds 28.97% of the shares, totaling 93,462,228 shares[7] Investment Activities - The company has committed to invest up to ¥500 million in low-risk short-term financial products, representing 30.17% of its audited net assets as of December 31, 2017[13] - As of the reporting period, the company had invested ¥459 million in entrusted wealth management, with all products maturing on time and no overdue amounts[14] - The company reported a decrease in cash flow from operating activities, with total cash inflows of CNY 443,998,148.85 in Q3 2019, down from CNY 575,357,040.80 in Q3 2018[37] Research and Development - R&D expenses for Q3 2019 amounted to ¥8,556,862.00, an increase of 14.3% compared to ¥7,487,730.68 in Q3 2018[28] - Research and development expenses increased to CNY 8.26 million in Q3 2019, up 18.4% from CNY 6.97 million in Q3 2018[33] - The company is conducting post-marketing clinical research on its benzalkonium chloride eye drops, with significant progress made in 2019, including approval of the clinical research plan[12] Tax and Other Income - Other income decreased by 65.05% to ¥1,312,500.00 from ¥3,755,383.38, mainly due to a reduction in government subsidies received[10] - The company experienced a 54.42% decrease in taxes paid, totaling ¥42,364,762.99 compared to ¥92,944,302.94 in the previous period[10] - The company reported a 99.99% decrease in tax refunds received, amounting to ¥291.26 compared to ¥4,725,379.65 in the previous year[10]